Answers are grounded in this paper and cite their sources.
Tumor endothelial cells (TECs) are active regulators of the tumor immune microenvironment, and their surfaces are enriched with diverse glycans. However, the influence of endothelial glycosylation on immune regulation remains poorly understood. Here, we show that sialyl Lewis X (sLeX) glycosylation of integrin α3 (ITGA3) in endothelial cells (ECs) promotes endothelial-to-mesenchymal transition (Endo-MT) by stabilizing Slug and repressing CDH5 transcription via the EGFR-AKT-GSK3β axis. This process is accompanied by downregulation of fatty aldehyde dehydrogenase (FALDH/ALDH3A2), with impaired fatty acid oxidation and decreased mitochondrial ROS. Reduced ROS levels attenuated the production of the pro-inflammatory cytokines IL-1β and IL-6, enhanced TGF-β production, and reduced Th1-like Th17 responses, thereby favoring Treg-like Th17 phenotypes. Functionally, endothelial sLeX-modified ITGA3 reshapes the immune microenvironment toward a regulatory immune phenotype. Collectively, these findings identify a link between endothelial glycosylation, metabolic reprogramming, and immune regulation, and suggest that sLeX-modified ITGA3 contributes to endothelial-mediated modulation of Th17-associated responses in bladder cancer.
No takes yet. Share an insight, caveat, or question.
Feng Guan (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: